The Implications of Dananamab for Patients

Lilly's Dananamab was designed so that patients could stop taking it when they've reached a certain threshold of amyloid clearance. More than half of people on the trial reached that level by one year, and I think almost three quarters reached it by a year and a half. And they were able to stop taking the drug. What do you guys think are the implications of that? We will have to wait to see as they follow these patients for longer in this study.